Paper12666
Tardive dyskinesia: are first signs reversible?
Quitkin F and 3 others. Am J Psychiatry, 1977. Cited by 110 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Tardive dyskinesia: are first signs reversible? Papers, record 12666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12666
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Dyskinesia, Drug-Induced | Major topic |
| Adult | |
| Chlorpromazine | |
| Female | |
| Fluphenazine | |
| Haloperidol | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Remission, Spontaneous |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 110 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33,754,644 | A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. | Schizophr Bull | 2021 | https://conductscience.org/library/papers/33754644 | PubMed |
| 33,213,556 | Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. | CNS Spectr | 2022 | https://conductscience.org/library/papers/33213556 | PubMed |
| 33,124,584 | Recent Advances in the Pharmacology of Tardive Dyskinesia. | Clin Psychopharmacol Neurosci | 2020 | https://conductscience.org/library/papers/33124584 | PubMed |
| 32,720,245 | Management of Tardive Syndrome: Medications and Surgical Treatments. | Neurotherapeutics | 2020 | https://conductscience.org/library/papers/32720245 | PubMed |
| 31,040,678 | Overcoming barriers to effective management of tardive dyskinesia. | Neuropsychiatr Dis Treat | 2019 | https://conductscience.org/library/papers/31040678 | PubMed |
| 30,357,723 | Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. | Drugs Aging | 2018 | https://conductscience.org/library/papers/30357723 | PubMed |
| 29,409,162 | Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. | Cochrane Database Syst Rev | 2018 | https://conductscience.org/library/papers/29409162 | PubMed |
| 25,374,768 | Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic. | Tremor Other Hyperkinet Mov (N Y) | 2014 | https://conductscience.org/library/papers/25374768 | PubMed |
| 21,289,825 | The management of neuroleptic-induced CNS effects. | Can Fam Physician | 1981 | https://conductscience.org/library/papers/21289825 | PubMed |
| 7,047,137 | Management of tardive dyskinesia: current update. | Drugs | 1982 | https://conductscience.org/library/papers/7047137 | PubMed |
| 6,110,535 | Adverse effects of antipsychotic agents. | Drugs | 1981 | https://conductscience.org/library/papers/6110535 | PubMed |
| 381,595 | Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia. | J Neurol Neurosurg Psychiatry | 1979 | https://conductscience.org/library/papers/381595 | PubMed |
| 280,396 | What's new in the psychopharmacology of schizophrenia. | Bull N Y Acad Med | 1978 | https://conductscience.org/library/papers/280396 | PubMed |
| 32,574 | Dopaminergic supersensitivity after neuroleptics: time-course and specificity. | Psychopharmacology (Berl) | 1978 | https://conductscience.org/library/papers/32574 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12666
GET https://conductscience.org/api/papers/v1/12666/authors